
|Videos|August 25, 2021
RVL Pharmaceuticals: Shifting toward ocular aesthetics
Author(s)David Hutton, Alex Delaney-Gesing
COO JD Schaub provides an overview of how RVL Pharmaceuticals has shifted toward becoming an ocular aesthetics company, with the sole purpose to fully focus on UPNEEQ®.
Advertisement
JD Schaub, chief operating officer at RVL Pharmaceuticals, provides an overview of how the company has shifted toward focusing on ocular aesthetics, along with the sole purpose to fully focus on UPNEEQ®, a prescription eye drop.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
DSLT for glaucoma and ocular hypertension: Real-world outcomes in 218 eyes
2
First patient dosed in phase 3 pivotal cohort of LIGHTHOUSE trial evaluating ATSN-201 for X-linked retinoschisis
3
NCX 470 gains positive regulatory feedback in China ahead of US NDA submission
4
Label Updates and Dosing Flexibility in Retinal Vascular Diseases
5























